You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for PREGABALIN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for PREGABALIN

Average Pharmacy Cost for PREGABALIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
PREGABALIN 300 MG CAPSULE 76282-0575-90 0.07162 EACH 2025-01-22
PREGABALIN 225 MG CAPSULE 76282-0574-90 0.06169 EACH 2025-01-22
PREGABALIN 200 MG CAPSULE 76282-0573-90 0.06158 EACH 2025-01-22
PREGABALIN 150 MG CAPSULE 76282-0572-90 0.05830 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for PREGABALIN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
PREGABALIN 100MG CAP,ORAL AvKare, LLC 69367-0327-09 90 11.93 0.13256 EACH 2023-06-15 - 2028-06-14 FSS
PREGABALIN 150MG CAP,ORAL AvKare, LLC 69367-0328-09 90 12.88 0.14311 EACH 2023-06-15 - 2028-06-14 FSS
PREGABALIN 200MG CAP,ORAL AvKare, LLC 69367-0329-09 90 14.31 0.15900 EACH 2023-06-15 - 2028-06-14 FSS
PREGABALIN 225MG CAP,ORAL AvKare, LLC 69367-0330-09 90 14.57 0.16189 EACH 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Pregabalin Market Analysis and Price Projections

Introduction to Pregabalin

Pregabalin is an anticonvulsant and anxiolytic drug widely used in the management and treatment of various neurological and psychiatric disorders, including epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. Here’s a comprehensive analysis of the pregabalin market, including its current state, growth prospects, and price projections.

Market Size and Growth Prospects

The global pregabalin market has been experiencing steady growth, driven by the increasing prevalence of neurological and psychiatric disorders.

  • Current Market Size: As of 2022, the global pregabalin market was valued at approximately $1.6 billion[2][4][5].
  • Forecasted Growth: The market is projected to reach $2.2 billion by 2032, with a Compound Annual Growth Rate (CAGR) of around 3% from 2023 to 2032[2][4][5].
  • Alternative Forecasts: Some reports suggest a slightly higher CAGR, such as 3.53% from 2024 to 2031, leading to a market size of $1,088.56 million by 2031[3], and 3.69% from 2024 to 2030, reaching $1,067.78 million by 2030[5].

Key Drivers of Market Growth

Several factors are driving the growth of the pregabalin market:

High Prevalence of Neurological Disorders

  • Epilepsy affects over 50 million individuals worldwide, with up to 70% of people living with epilepsy potentially avoiding seizures with proper diagnosis and treatment[2][4].
  • Neuropathic pain, which affects 3% to 17% of the general population, is another significant driver. Diabetic polyneuropathy, in particular, is common, with approximately 50% of patients with diabetes expected to develop neuropathy[1].

Increasing Demand in Developing Regions

  • The Asia-Pacific region is expected to register the fastest CAGR due to rising healthcare expenditures and technological advancements. Countries like China, India, and Southeast Asian nations are experiencing an increase in the incidence of epilepsy and neuropathic pain[2][4].

Introduction of Generic Versions

  • The approval and launch of generic pregabalin products, such as those by Lupin Pharmaceuticals, are anticipated to drive market growth due to their cost-effectiveness and increased availability[1].

Market Segmentation

The pregabalin market is segmented based on several criteria:

Application

  • The neuropathic pain segment accounts for the largest share, contributing more than two-thirds of the global pregabalin market revenue. This segment is expected to maintain its lead position during the forecast period due to the efficient management of neuropathic pain[4].
  • Other significant applications include epilepsy, anxiety disorders, and fibromyalgia[3][5].

Dosage Forms

  • Oral dosage forms, such as capsules and tablets, dominate the market due to their rising demand and ease of administration[3].

Distribution Channels

  • Drug stores and retail pharmacies currently hold the largest share, but the online pharmacy segment is expected to register the highest CAGR due to convenience, availability, and higher discounts[4].

Regional Insights

North America

  • North America dominates the global pregabalin market in terms of revenue, driven by its advanced healthcare infrastructure, substantial investments in R&D, and the presence of major industry players[2][5].

Asia-Pacific

  • This region is expected to grow at the highest CAGR, driven by an increase in patient populations suffering from epilepsy and neuropathic pain, along with rapid technological advancements[2][4].

Challenges and Restraints

Despite the growth prospects, the pregabalin market faces several challenges:

Alternative Treatments

  • The availability of alternative treatments for neurological and psychiatric disorders can restrain market growth[1].

Adverse Effects

  • Pregabalin is associated with adverse effects such as sleepiness and visual disturbances, which can deter some patients[5].

Regulatory Policies

  • Stringent regulatory policies can also act as a restraint on the market[1].

Key Players

The pregabalin market is competitive, with several major players:

  • Teva Pharmaceuticals
  • Cipla Limited
  • Medley Pharmaceuticals Limited
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC[1].

Price Projections

The cost-effectiveness of pregabalin, especially with the introduction of generic versions, is expected to influence market growth.

  • Generic Impact: The launch of generic pregabalin products is anticipated to reduce prices, making the drug more accessible and driving market growth[1].
  • Market Competition: Increased competition among market players, particularly with the entry of new generic versions, is likely to stabilize or reduce prices over the forecast period[3].

Key Takeaways

  • The global pregabalin market is expected to grow significantly, driven by the high prevalence of neurological and psychiatric disorders.
  • The Asia-Pacific region is projected to be the fastest-growing market.
  • Generic versions of pregabalin are expected to drive market growth due to their cost-effectiveness.
  • North America currently dominates the market but faces increasing competition from emerging regions.
  • The neuropathic pain segment is the largest and is expected to maintain its lead position.

FAQs

What is the current size of the global pregabalin market?

The global pregabalin market was valued at approximately $1.6 billion in 2022[2][4][5].

What is the projected CAGR for the pregabalin market from 2023 to 2032?

The pregabalin market is projected to grow at a CAGR of around 3% from 2023 to 2032[2][4].

Which region is expected to grow at the highest CAGR in the pregabalin market?

The Asia-Pacific region is expected to register the highest CAGR during the forecast period[2][4].

What are the primary applications of pregabalin?

Pregabalin is primarily used to treat epilepsy, neuropathic pain, anxiety disorders, and fibromyalgia[3][5].

Who are the major players in the pregabalin market?

Major players include Teva Pharmaceuticals, Cipla Limited, Medley Pharmaceuticals Limited, Viatris Inc., and Amneal Pharmaceuticals LLC[1].

Sources

  1. Mordor Intelligence: Pregabalin Market Size & Share Analysis - Growth Trends
  2. Allied Market Research: Pregabalin Market Size, Segments Analysis | Forecast - 2032
  3. Data Bridge Market Research: Global Pregabalin Market – Industry Trends and Forecast to 2031
  4. GlobeNewswire: Pregabalin Market to Reach $2.2 Billion Globally, By 2032 at 3% CAGR - Allied Market Research
  5. Maximize Market Research: Pregabalin Market: Industry Analysis and Forecast (2024-2030)

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.